Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Iran War Drives Asia's Plastic Crisis — and a Green Packaging Boom 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
Elliott Investment Takes ~3% Stake in Daikin, Pushes for Buybacks and Strategic Overhaul 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Dublin, April 07, 2016 -- Research and Markets has announced the addition of Jain PharmaBiotech's new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering.
Drug delivery remains a challenge in management of cancer. Approximately 12.5 million new cases of cancer are being diagnosed worldwide each year and considerable research is in progress for drug discovery for cancer. Cancer drug delivery is no longer simply wrapping up cancer drugs in a new formulations for different routes of delivery. The focus is on targeted cancer therapy. The newer approaches to cancer treatment not only supplement the conventional chemotherapy and radiotherapy but also prevent damage to normal tissues and prevent drug resistance.
The market value of drug delivery technologies and the anticancer drugs are difficult to separate. Cancer market estimates from 2015-2025 are given according to organs involved and the types of cancer as well as according to technologies. Distribution of the into major regions is also described.
Profiles of 230 companies involved in developing innovative cancer therapies and methods of delivery are presented along with their 268 collaborations. The bibliography contains over 650 publications that are cited in the report.The report is supplemented with 66 tables and 12 figures.
Key Topics Covered:
Part I: Technologies & Markets
Executive Summary
1. Introduction to cancer therapy
2. Innovative treatments for cancer
3. Drug delivery systems for cancer
4. Delivery of Biological Therapies for Cancer
5. Delivery strategies according to cancer type and location
6. Cancer drug delivery markets
7. References
Part II: Companies
8. Companies involved in cancer drug delivery
For more information visit http://www.researchandmarkets.com/research/7w4tsr/drug_delivery_in
Source: Jain PharmaBiotech
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Drug Delivery, Oncology
